Key Points
- Insider Adam Crystal sold 5,000 Tango Therapeutics shares at an average of $25, totaling $125,000; he retained 115,743 shares after the transaction.
- Crystal had also sold 5,000 shares on November 2 and 27,000 shares on October 1, according to the article.
- Tango reported a quarterly loss of $0.39 per share, missing analyst expectations of a $0.35 loss. Analysts’ average rating was “Moderate Buy,” with a consensus price target of $45.54.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 5,000 shares of the firm's stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the insider owned 115,743 shares of the company's stock, valued at $2,893,575. This trade represents a 4.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Adam Crystal also recently made the following trade(s):
- On Monday, November 2nd, Adam Crystal sold 5,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $22.42, for a total transaction of $112,100.00.
- On Thursday, October 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $24.47, for a total transaction of $660,690.00.
Tango Therapeutics Price Performance
Shares of NASDAQ TNGX traded up $0.65 on Friday, hitting $25.50. The company's stock had a trading volume of 2,706,112 shares, compared to its average volume of 4,241,986. The stock has a 50 day moving average of $23.53 and a 200-day moving average of $22.79. The company has a market capitalization of $4.32 billion, a price-to-earnings ratio of -18.61 and a beta of 1.26. Tango Therapeutics, Inc. has a 12-month low of $7.60 and a 12-month high of $34.39.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.04). Sell-side analysts expect that Tango Therapeutics, Inc. will post -1.46 EPS for the current fiscal year.
Hedge Funds Weigh In On Tango Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the company. Nykredit A S purchased a new stake in Tango Therapeutics in the 2nd quarter worth approximately $26,000. Allworth Financial LP purchased a new position in shares of Tango Therapeutics during the 2nd quarter worth $35,000. Sterling Capital Management LLC lifted its stake in shares of Tango Therapeutics by 838.8% during the 3rd quarter. Sterling Capital Management LLC now owns 4,647 shares of the company's stock worth $116,000 after purchasing an additional 4,152 shares during the period. Global Retirement Partners LLC acquired a new stake in shares of Tango Therapeutics during the second quarter worth $122,000. Finally, State of Wyoming acquired a new stake in shares of Tango Therapeutics during the first quarter worth $128,000. Hedge funds and other institutional investors own 78.99% of the company's stock.
Trending Headlines about Tango Therapeutics
Here are a few of the latest headlines about TNGX:
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on the company. Zacks Research downgraded Tango Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 27th. HC Wainwright cut their price target on Tango Therapeutics from $68.00 to $67.00 and set a "buy" rating for the company in a report on Tuesday, November 10th. Guggenheim upped their price objective on Tango Therapeutics from $32.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. William Blair initiated coverage on Tango Therapeutics in a research note on Friday, October 16th. They set an "outperform" rating on the stock. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $65.00 price objective on shares of Tango Therapeutics in a research note on Tuesday. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $45.54.
Check Out Our Latest Report on TNGX
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
